Spyre Therapeutics Stock Forecast
NASDAQ: SYREHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
SYRE analyst consensus
Consensus (17 analysts)
strong_buy
Avg. price target
$120.21+40.28%
- Strong buy 1
- Buy 15
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 17 Wall Street analysts covering Spyre Therapeutics (2026-10-07), 16 rate the stock a buy or strong buy, 1 rate it a hold and 0 rate it a sell or strong sell, for a consensus rating of "strong_buy". The average 12-month price target is $120.21, with a high estimate of $130.00 and a low estimate of $97.00. The average target implies upside of 40.3% from the current price of $85.69.
The spread between the highest and lowest targets is 34.0%, a relatively narrow range. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for SYRE.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 1 | 6% |
| Buy | 15 | 88% |
| Hold | 1 | 6% |
| Sell | 0 | 0% |
| Strong sell | 0 | 0% |
Ratings as of 2026-10-07.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $97.00 | +13.20% |
| Average target | $120.21 | +40.28% |
| High target | $130.00 | +51.71% |